Navigation Links
Global Lung Cancer Therapeutics Market 2012-2016
Date:2/12/2013

NEW YORK, Feb. 12, 2013 /PRNewswire/ -- Reportlinker.com announces that a new market research report is available in its catalogue:

Global Lung Cancer Therapeutics Market 2012-2016

http://www.reportlinker.com/p01095396/Global-Lung-Cancer-Therapeutics-Market-2012-2016.html#utm_source=prnewswire&utm_medium=pr&utm_campaign=Therapy

TechNavio's analysts forecast the Global Lung Cancer Therapeutics market to grow at a CAGR of 13.26 percent over the period 2012-2016. One of the key factors contributing to this market growth is the significant growth of the Lung Cancer Therapeutics market in the US. The Global Lung Cancer Therapeutics market has also been witnessing an increase in the number of MandAs. However, the adversative side effects of lung cancer therapeutic drugs could pose a challenge to the growth of this market.

TechNavio's report, the Global Lung Cancer Therapeutics Market 2012-2016, has been prepared based on an in-depth analysis of the market with inputs from industry experts. The report covers the Americas, and the EMEA and APAC regions; it also covers the Global Lung Cancer Therapeutics market landscape and its growth prospects in the coming years. The report also includes a discussion of the key vendors operating in this market.

The key vendors dominating this market space are AstraZeneca plc, Bristol-Myers Squibb Co., Eli Lilly and Co., GlaxoSmithKline plc, Hoffmann-La Roche Ltd., and Novartis AG.

The other vendors mentioned in the report are

Ambit Biosciences Inc., ARIAD Pharmaceuticals Inc., Biogen Idec Inc., Cephalon Inc., Clavis Pharma ASA, Eisai Co. Ltd., ERYtech Pharma SA, Genmab A/S, Genzyme Corp., Pfizer Inc., Sunesis Pharmaceuticals Inc., Talon Therapeutics Inc., and Teva Pharmaceutical Industries Ltd.

Key questions answered in this report:

What will the market size be in 2016 and what will the growth rate be?

What are the key market trends?

What is driving this market?

What are the challenges to market growth?

Who are the key vendors in this market space?

What are the market opportunities and threats faced by the key vendors?

What are the strengths and weaknesses of the key vendors?

Table of Contents 01. Executive Summary

02. Introduction

03. Market Coverage

Market Overview

Key Products

04. Market Landscape

Market Size

Market Forecast

04.1 Five Forces Analysis

05. Geographical Segmentation

06. Key Leading Countries

US

Germany

Japan

07. Rate of Incidence and Prevalence

08. Vendor Landscape

09. Buying Criteria

10. Market Growth Drivers

11. Drivers and their Impact

12. Market Challenges

13. Impact of Drivers and Challenges

14. Market Trends

15. Key Vendor Analysis

15.1 Hoffmann-La Roche Ltd.

Business Overview

Key Information

SWOT Analysis

15.2 Eli Lilly and Co.

Business Overview

Key Information

SWOT Analysis

15.3 Sanofi S.A.

Business Overview

Key Information

SWOT Analysis

15.4 Bristol-Myers Squibb Co.

Business Overview

Key Information

SWOT Analysis

15.5 AstraZeneca plc

Business Overview

Key Information

SWOT Analysis

15.6 Novartis AG

Business Overview

Key Information

SWOT Analysis

15.7 GlaxoSmithKline plc

Business Overview

Key Information

SWOT Analysis

16. Other Reports in this Series

List of Exhibits: Exhibit 1: Global Lung Cancer Therapeutics Market 2012-2016 (US$ billion)

Exhibit 2: Global Lung Cancer Therapeutics Market by Geographical Segmentation 2012

Exhibit 3: Global Lung Cancer Therapeutics Market by Vendor Segmentation 2012

Exhibit 4: Global Lung Cancer Therapeutics Market by Leading Drugs Segmentation 2012

Exhibit 5: Business Segmentation of Hoffmann-La Roche Ltd.

Exhibit 6: Business Segmentation of Eli Lilly and Co.

Exhibit 7: Business Segmentation of Sanofi S.A.

Exhibit 8: Business Segmentation of Bristol-Myers Squibb Co.

Exhibit 9: Business Segmentation of AstraZeneca plc

Exhibit 10: Business Segmentation of Novartis AG

Exhibit 11: Business Segmentation of GlaxoSmithKline plc

To order this report:Therapy Industry: Global Lung Cancer Therapeutics Market 2012-2016

Contact Clare: clare@reportlinker.com

US:(339) 368 6001

Intl:+1 339 368 6001


'/>"/>
SOURCE Reportlinker
Copyright©2012 PR Newswire.
All rights reserved

Related medicine technology :

1. Perrigo Company To Present At The Leerink Swann Global Healthcare Conference
2. Natalie Douglas, CEO of Idis, Joins Global Genes
3. RARE Project Board of Directors
4. Natalie Douglas, CEO von Idis, tritt Vorstand von Global Genes
5. RARE Project bei
6. Covance To Present At The Leerink Swann Global Healthcare Conference
7. Thoratec Presentation at Leerink Swann Global Healthcare Conference to Be Webcast
8. CPhI Announces its 2nd Annual Global Pharma Regulatory Summit
9. Array BioPharma To Present At The Leerink Swann Global Healthcare Conference
10. Quest Diagnostics To Speak At The Leerink Swann Global Healthcare Conference 2013
11. HeartWare Presentation at Leerink Swann Global Healthcare Conference to be Webcast
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:6/7/2017)... -- Endo International plc (NASDAQ: ENDP ) ... Joseph R. Goodwin , U.S. District Court Judge for ... , entered a case management order in MDL 2325, ... Litigation (the "MDL") that includes a provision requiring plaintiffs ... on specific causation within one hundred twenty (120) days ...
(Date:6/3/2017)... 2017  Eli Lilly and Company (NYSE: ... the Phase 3 MONARCH 2 study showed that ... in combination with fulvestrant, significantly improved progression-free survival ... women with hormone-receptor-positive (HR+), human epidermal growth factor ... relapsed or progressed after endocrine therapy (median PFS, ...
(Date:5/30/2017)... AVIV, Israel , May 30, 2017 ... stage pharmaceutical Company specializing in the development of ... will present a company overview at three upcoming ... The 7th Annual LD Micro Invitational: ... Date:                     ...
Breaking Medicine Technology:
(Date:6/23/2017)... ... June 23, 2017 , ... Radabaugh & Associates, a locally ... business owners in North Central West Virginia, is embarking on a cooperative charity ... residents in the region. , The Stepping Stones organization offers a series of ...
(Date:6/22/2017)... ... 2017 , ... Plastic Surgery Associates is proud to report that founding surgeon, ... research and information firm, Castle Connolly, releases their list of the most notable and ... 3rd time that Dr. Canales has been recognized by Castle Connolly. , ...
(Date:6/22/2017)... ... June 22, 2017 , ... ... from the American Heart Association (AHA) to launch a Rheumatic Heart Disease Center, ... prevention and diagnosis of rheumatic heart disease (RHD) in high-risk, financially disadvantaged countries ...
(Date:6/22/2017)... , ... June 22, 2017 , ... ... announced today that it has received certification for ANSI/ASIS PSC.1-2012. The company’s work ... in environments where the rule of law has been degraded. The PSC.1 standard ...
(Date:6/20/2017)... ... June 20, 2017 , ... TwelveStone Health Partners, ... a Nashville-based private equity firm, has invested $3.35 million in the company. ... and Claritas Capital offers the smart money, speed to market and accountability we ...
Breaking Medicine News(10 mins):